

A GUIDE TO MENINGOCOCCAL VACCINATIONS

For Patients Treated With Alexion Complement Inhibitors



WHY SHOULD I BE VACCINATED?

People at higher risk for meningococcal infections should receive meningococcal vaccinations routinely.

Receiving treatment with a type of medicine called a complement inhibitor is a risk factor for meningococcal infections. The complement system is the body's defense against *Neisseria meningitidis*, a type of bacteria that can cause meningococcal disease. But complement inhibitors suppress the complement system. That makes people taking this type of medicine more susceptible to meningococcal infections.¹⁻⁴

That's why receiving meningococcal vaccinations is an important step in receiving the treatment you need.^{3,4}

WHERE CAN I GET VACCINATED?



Sign up at [AlexionOneSource.com](https://www.AlexionOneSource.com) or call [1.888.765.4747](tel:18887654747) to get vaccination support from OneSource™, a free and personalized patient support program offered by Alexion.







OneSource can help you locate places to receive your vaccine:

- ✓ Your treating physician or family doctor's office
- ✓ A pharmacy near you
- ✓ The same place you get your infusion
- ✓ Your local health department

WHAT DO I NEED TO KNOW ABOUT THE VACCINATION SCHEDULE?

There are two types of meningococcal vaccines available in the United States, MenACWY and MenB, which protect against different types of bacteria that cause meningitis.⁵

The Advisory Committee on Immunization Practices (ACIP) recommends that adults and children over 10 years old at increased risk should receive **both types** of meningococcal vaccines (MenACWY and MenB) **at least 2 weeks prior** to receiving the first infusion with a complement inhibitor.¹

VACCINE	PRIMARY VACCINATION	BOOSTER VACCINATION
MenACWY (Menveo, MenQuadfi) ⁶	 2 doses at least 8 weeks apart	 1 dose every 5 years if risk remains
+		
MenB-4C (Bexsero) ⁶	 2 doses at least 1 month apart	 1 dose 1 year following completion of primary series and every 2 to 3 years if risk remains
OR		
MenB-FHbp (Trumenba) ⁶	 3 doses 0, 1-2, and 6 months apart*	 1 dose 1 year following completion of primary series and every 2 to 3 years if risk remains

*For MenB-FHbp, if dose 2 was administered at least 6 months after dose 1, dose 3 is not needed.

For information on the vaccine schedule for children 10 years old or younger, please contact the treating physician.



Please see additional Important Safety Information on page 3, see accompanying full Prescribing Information, scan QR Code, or visit www.ultomiris.com/PI for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.

A GUIDE TO MENINGOCOCCAL VACCINATIONS

For Patients Treated With Alexion Complement Inhibitors



SUPPORT AT EVERY STEP OF YOUR JOURNEY

OneSource™, a free and personalized patient support program from Alexion, is designed to support your specific needs.

OneSource can help you find a place to get vaccinated, assist with navigating your insurance plan or other resources for covering the vaccination costs, and give you useful tools and information about meningococcal vaccinations.

CALL: **1.888.765.4747**



VISIT: **AlexionOneSource.com**



Scan the QR code above with the camera on your mobile device to access and save the OneSource website and contact information.

To learn more, ask OneSource about a Patient Education Manager (PEM) in your area. The local PEM is available to meet with you one-on-one, virtually or in person, or connect with you at local educational sessions and events.

STAY ON TOP OF YOUR VACCINATIONS

- ✓ **Stay up to date**
Enroll in OneSource. A dedicated support team is here to provide information about the most up-to-date ACIP recommendations for meningococcal vaccinations, help with vaccination or treatment logistics, and ongoing support.
- ✓ **Keep track**
Call OneSource and ask for a free Meningococcal Vaccination Card. Tracking your vaccines will help you understand which vaccines you may still need and allow you to share your vaccination history with your healthcare team.
- ✓ **Carry a Safety Card**
Ask OneSource or your doctor for a Safety Card about your meningococcal infection risk. Fill it out and always carry it with you. Show the card to any doctor or nurse who treats you. This will help them diagnose and treat you quickly.



QUESTIONS YOU MAY ASK YOUR DOCTOR

- How and where can I get vaccinated?
- Who will provide me with a vaccination prescription?
- What are my next steps for getting vaccinated?
- What type of meningococcal vaccines will I receive?
- What do I need if I was vaccinated in the past?
- Do I need boosters before switching Alexion therapies?

References:

1. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. *MMWR Recomm Rep.* 2020;69(9):1-41.
2. Uria JM, Zhang Q, Li Y, et al. A generic mechanism in *Neisseria meningitidis* for enhanced resistance against bactericidal antibodies. *J Exp Med.* 2008;205(6):1423-1434.
3. ULTOMIRIS. Prescribing Information. Alexion Pharmaceuticals, Inc.
4. SOLIRIS. Prescribing Information. Alexion Pharmaceuticals, Inc.
5. Centers for Disease Control and Prevention. Meningococcal vaccination: what everyone should know. Updated October 12, 2021. Accessed February 28, 2023. <https://www.cdc.gov/vaccines/vpd/mening/public/index.html>
6. Centers for Disease Control and Prevention. Recommended adult immunization schedules 2022. Updated February 17, 2022. Accessed January 23, 2023. <https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf>



Please see additional Important Safety Information on page 4, see accompanying full Prescribing Information, scan QR Code, or visit www.soliris.net/PI for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections.

US/ALL/0648 V2 09/2023

INDICATIONS & IMPORTANT SAFETY INFORMATION FOR ULTOMIRIS® (ravulizumab-cwvz)

INDICATIONS

What is ULTOMIRIS?

ULTOMIRIS is a prescription medicine used to treat:

- adults and children 1 month of age and older with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).
- adults and children 1 month of age and older with a disease called atypical Hemolytic Uremic Syndrome (aHUS). ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
- adults with a disease called generalized Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.

It is not known if ULTOMIRIS is safe and effective in children younger than 1 month of age.

It is not known if ULTOMIRIS is safe and effective for the treatment of gMG in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about ULTOMIRIS?

ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

- ULTOMIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.
- You must receive meningococcal vaccines at least 2 weeks before your first dose of ULTOMIRIS if you are not vaccinated.
 - If your healthcare provider decided that urgent treatment with ULTOMIRIS is needed, you should receive meningococcal vaccination as soon as possible.
 - If you have not been vaccinated and ULTOMIRIS therapy must be initiated immediately, you should also receive 2 weeks of antibiotics with your vaccinations.
 - If you had a meningococcal vaccine in the past, you might need additional vaccination. Your healthcare provider will decide if you need additional vaccination.
 - Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your healthcare provider or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms and eyes sensitive to light.

Your healthcare provider will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 8 months after your last ULTOMIRIS dose. It is important to show this card to any healthcare provider or nurse to help them diagnose and treat you quickly.

ULTOMIRIS is only available through a program called the ULTOMIRIS REMS. Before you can receive ULTOMIRIS, your healthcare provider must: enroll in the ULTOMIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a **Patient Safety Card** about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with a meningococcal vaccine, and if needed, get revaccinated with the meningococcal vaccine. Ask your healthcare provider if you are not sure if you need to be revaccinated.

ULTOMIRIS may also increase the risk of other types of serious infections. Make sure your child receives vaccinations against *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib) if treated with ULTOMIRIS. Call your healthcare provider right away if you have any new signs or symptoms of infection.

Who should not receive ULTOMIRIS?

Do not receive ULTOMIRIS if you have a meningococcal infection or have not been vaccinated against meningococcal infection unless your healthcare provider decides that urgent treatment with ULTOMIRIS is needed.

Before you receive ULTOMIRIS, tell your healthcare provider about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if ULTOMIRIS will harm your unborn baby or if it passes into your breast milk. You should not breastfeed during treatment and for 8 months after your final dose of ULTOMIRIS.

Tell your healthcare provider about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment.

If you have PNH and you stop receiving ULTOMIRIS, your healthcare provider will need to monitor you closely for at least 16 weeks after you stop ULTOMIRIS. Stopping ULTOMIRIS may cause breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in your red blood cell count, tiredness, blood in your urine, stomach-area (abdomen) pain, shortness of breath, blood clots, trouble swallowing, and erectile dysfunction (ED) in males.

If you have aHUS, your healthcare provider will need to monitor you closely for at least 12 months after stopping treatment for signs of worsening aHUS or problems related to a type of abnormal clotting and breakdown of your red blood cells called thrombotic microangiopathy (TMA). Symptoms or problems that can happen with TMA may include: confusion or loss of consciousness, seizures, chest pain (angina), difficulty breathing and blood clots or stroke.

What are the possible side effects of ULTOMIRIS?

ULTOMIRIS can cause serious side effects including infusion-related reactions. Symptoms of an infusion-related reaction with ULTOMIRIS may include lower back pain, tiredness, feeling faint, discomfort in your arms or legs, bad taste, or drowsiness. Stop treatment of ULTOMIRIS and tell your healthcare provider or nurse right away if you develop these symptoms, or any other symptoms during your ULTOMIRIS infusion that may mean you are having a serious infusion reaction, including: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out.

The most common side effects of ULTOMIRIS in people treated for PNH are upper respiratory tract infection and headache.

The most common side effects of ULTOMIRIS in people treated for aHUS are upper respiratory tract infection, diarrhea, nausea, vomiting, headache, high blood pressure and fever.

The most common side effects of ULTOMIRIS in people with gMG are diarrhea and upper respiratory tract infections.

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of ULTOMIRIS. For more information, ask your healthcare provider or pharmacist. Call your healthcare provider right away if you miss an ULTOMIRIS infusion or for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.



Please see additional Important Safety Information on page 3, see accompanying full Prescribing Information, scan QR Code, or visit www.ultomiris.com/PI for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections/sepsis.

US/ALL/0648 V2 09/2023

INDICATIONS & IMPORTANT SAFETY INFORMATION FOR SOLIRIS® (eculizumab)

INDICATIONS

What is SOLIRIS?

SOLIRIS is a prescription medicine used to treat:

- patients with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).
- adults and children with a disease called atypical Hemolytic Uremic Syndrome (aHUS). SOLIRIS is not for use in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).
- adults with a disease called generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
- adults with a disease called neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive.

It is not known if SOLIRIS is safe and effective in children with PNH, gMG, or NMOSD.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SOLIRIS?

SOLIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections.

- SOLIRIS increases your chance of getting serious and life-threatening meningococcal infections that may quickly become life-threatening and cause death if not recognized and treated early.**

- You must receive meningococcal vaccines at least 2 weeks before your first dose of SOLIRIS if you are not vaccinated.
- If your doctor decided that urgent treatment with SOLIRIS is needed, you should receive meningococcal vaccination as soon as possible.
- If you have not been vaccinated and SOLIRIS therapy must be initiated immediately, you should also receive two weeks of antibiotics with your vaccinations.
- If you had a meningococcal vaccine in the past, you might need additional vaccination. Your doctor will decide if you need additional vaccination.
- Meningococcal vaccines reduce but do not prevent all meningococcal infections. Call your doctor or get emergency medical care right away if you get any of these signs and symptoms of a meningococcal infection: headache with nausea or vomiting, headache and fever, headache with a stiff neck or stiff back, fever, fever and a rash, confusion, muscle aches with flu-like symptoms, and eyes sensitive to light.

Your doctor will give you a Patient Safety Card about the risk of meningococcal infection. Carry it with you at all times during treatment and for 3 months after your last SOLIRIS dose. It is important to show this card to any doctor or nurse to help them diagnose and treat you quickly.

SOLIRIS is only available through a program called the SOLIRIS REMS.

Before you can receive SOLIRIS, your doctor must enroll in the SOLIRIS REMS program; counsel you about the risk of meningococcal infection; give you information and a **Patient Safety Card** about the symptoms and your risk of meningococcal infection (as discussed above); and make sure that you are vaccinated with the meningococcal vaccine and, if needed, get revaccinated with the meningococcal vaccine. Ask your doctor if you are not sure if you need to be revaccinated.

SOLIRIS may also increase the risk of other types of serious infections. Make sure your child receives vaccinations against *Streptococcus pneumoniae* and *Haemophilus influenzae* type b (Hib) if treated with SOLIRIS. Certain people may be at risk of serious infections with gonorrhea. Certain fungal infections (*Aspergillus*)

may occur if you take SOLIRIS and have a weak immune system or a low white blood cell count.

Who should not receive SOLIRIS?

Do not receive SOLIRIS if you have a meningococcal infection or have not been vaccinated against meningitis infection unless your doctor decides that urgent treatment with SOLIRIS is needed.

Before you receive SOLIRIS, tell your doctor about all of your medical conditions, including if you: have an infection or fever, are pregnant or plan to become pregnant, and are breastfeeding or plan to breastfeed. It is not known if SOLIRIS will harm your unborn baby or if it passes into your breast milk.

Tell your doctor about all the vaccines you receive and medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements which could affect your treatment. It is important that you have all recommended vaccinations before you start SOLIRIS, receive 2 weeks of antibiotics if you immediately start SOLIRIS, and stay up-to-date with all recommended vaccinations during treatment with SOLIRIS.

If you have PNH, your doctor will need to monitor you closely for at least 8 weeks after stopping SOLIRIS. Stopping treatment with SOLIRIS may cause breakdown of your red blood cells due to PNH. Symptoms or problems that can happen due to red blood cell breakdown include: drop in the number of your red blood cell count, drop in your platelet count, confusion, kidney problems, blood clots, difficulty breathing, and chest pain.

If you have aHUS, your doctor will need to monitor you closely during and for at least 12 weeks after stopping treatment for signs of worsening aHUS symptoms or problems related to abnormal clotting (thrombotic microangiopathy). Symptoms or problems that can happen with abnormal clotting may include: stroke, confusion, seizure, chest pain (angina), difficulty breathing, kidney problems, swelling in arms or legs, and a drop in your platelet count.

What are the possible side effects of SOLIRIS?

SOLIRIS can cause serious side effects including serious infusion-related reactions. Tell your doctor or nurse right away if you get any of these symptoms during your SOLIRIS infusion: chest pain, trouble breathing or shortness of breath, swelling of your face, tongue, or throat, and feel faint or pass out. If you have an infusion-related reaction to SOLIRIS, your doctor may need to infuse SOLIRIS more slowly, or stop SOLIRIS.

The most common side effects in people with PNH treated with SOLIRIS include: headache, pain or swelling of your nose or throat (nasopharyngitis), back pain, and nausea.

The most common side effects in people with aHUS treated with SOLIRIS include: headache, diarrhea, high blood pressure (hypertension), common cold (upper respiratory infection), stomach-area (abdominal) pain, vomiting, pain or swelling of your nose or throat (nasopharyngitis), low red blood cell count (anemia), cough, swelling of legs or feet (peripheral edema), nausea, urinary tract infections, and fever.

The most common side effects in people with gMG treated with SOLIRIS include: muscle and joint (musculoskeletal) pain.

The most common side effects in people with NMOSD treated with SOLIRIS include: common cold (upper respiratory infection), pain or swelling of your nose or throat (nasopharyngitis), diarrhea, back pain, dizziness, flu like symptoms (influenza) including fever, headache, tiredness, cough, sore throat, and body aches, joint pain (arthralgia), throat irritation (pharyngitis), and bruising (contusion).

Tell your doctor about any side effect that bothers you or that does not go away. These are not all the possible side effects of SOLIRIS. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch, or call 1-800-FDA-1088.



Please see additional Important Safety Information on page 4, see accompanying full Prescribing Information, scan QR Code, or visit www.soliris.net/PI for SOLIRIS, including Boxed WARNING regarding serious and life-threatening meningococcal infections.

This information is intended for United States residents only. ULTOMIRIS, the ULTOMIRIS logo, SOLIRIS, ALEXION, the Alexion logo, and the OneSource logo are registered trademarks of Alexion Pharmaceuticals, Inc., and OneSource is a trademark of Alexion Pharmaceuticals, Inc.

© 2023, Alexion Pharmaceuticals, Inc. All rights reserved. US/ALL/0648 V2 09/2023